RSS und Atom Feed Reader Online

International Pharmaceutical Industry

Peer Reviewed, Contemporary, Authoritative

Merck jumps back into Alzheimer’s waters with Cerevance pact

Merck (MSD) has inked a multi-year strategic research collaboration with Massachusetts-based Cerevance, marking Merck’s biggest move in the Alzheimer’s space in years. The deal involves the partners working together to use Cerevance’s proprietary Nuclear Enriched Transcript Sort sequencing (NETSseq) technology platform to identify novel targets for Alzheimer’s disease. The CNS-focused developer will out-license one discovery-stage program to Merck as part of the collaboration. […]

The post Merck jumps back into Alzheimer’s waters with Cerevance pact appeared first on International Pharmaceutical Industry.

Veröffentlicht am 10.08.2022 um 10:44:39 Uhr - Kategorie: News - Autor: theArchitect

MacroGenics to cut workforce, close satellite sites

MacroGenics has initiated cost-saving measures through a corporate restructuring, announcing job cuts and the closure of two satellite facilities. The planned measures include an approximate 15% workforce reduction in employees and the closure of two satellite sites — a Brisbane, California-based research site and a smaller-scale, non-commercial GMP manufacturing site in Rockville, Maryland. This comes on […]

The post MacroGenics to cut workforce, close satellite sites appeared first on International Pharmaceutical Industry.

Veröffentlicht am 10.08.2022 um 10:38:30 Uhr - Kategorie: News - Autor: theArchitect

AstraZeneca, Daiichi Sankyo grab first FDA approval for targeted HER2-low breast cancer drug

The U.S. FDA has approved the first targeted therapy for patients with HER2-low breast cancer, AstraZeneca and Daiichi Sankyo’s Enhertu. Enhertu is now available as a third third-line treatment for women with advanced HER2-positive breast cancer. HER2-low breast cancer is a newly defined subset of HER2-negative breast cancer, which means the tumours do not over-express the HER2 […]

The post AstraZeneca, Daiichi Sankyo grab first FDA approval for targeted HER2-low breast cancer drug appeared first on International Pharmaceutical Industry.

Veröffentlicht am 10.08.2022 um 10:36:55 Uhr - Kategorie: News - Autor: theArchitect

SyneuRx reveals results of COVID-19 candidate trial

Positive data show Pentarlandir is safe and effective in patients with mild-to-moderate COVID-19. SyneuRx – a company focused on the development of drugs for COVID-19 and multiple central nervous system disorders – has announced results from its phase 2 clinical trial evaluating the efficacy and safety of SNB01, a novel COVID-19 oral antiviral candidate. 89 […]

The post SyneuRx reveals results of COVID-19 candidate trial appeared first on International Pharmaceutical Industry.

Veröffentlicht am 10.08.2022 um 10:34:21 Uhr - Kategorie: News - Autor: theArchitect

EQRx announces further results from phase 3 trial of sugemalimab

The study involved patients with locally advanced, unresectable stage 3 non-small cell lung cancer. EQRx has announced a late-breaking oral presentation of updated data from its phase 3 GEMSTONE-301 trial of sugemalimab in non-small cell lung cancer (NSCLC). In the updated results from the study, which follow the original data cut off from March 2022, […]

The post EQRx announces further results from phase 3 trial of sugemalimab appeared first on International Pharmaceutical Industry.

Veröffentlicht am 10.08.2022 um 10:32:43 Uhr - Kategorie: News - Autor: theArchitect

CPHI Frankfurt

1 – 3 November 2022 Messe Frankfurt, Germany The biggest international pharma industry event is back! Unlock endless business opportunities at CPHI Frankfurt, 1 – 3 November 2022. In 2022, CPhI Worldwide will become CPHI Frankfurt: a 3-day event that will take place in person and online to help you get the most out of […]

The post CPHI Frankfurt appeared first on International Pharmaceutical Industry.

Veröffentlicht am 05.08.2022 um 12:41:44 Uhr - Kategorie: Industry events - Autor: theArchitect

Neil Jones is appointed as the new Chief Commercial Officer (CCO) of Aenova Group

Neil Jones has been the new Chief Commercial Officer (CCO) of Aenova Group since July 18, 2022. As a member of the Executive Leadership Team (ELT), he will play a key role in shaping the future and commercial success of Aenova Group and will report directly to CEO Jan Kengelbach in his role.   Starnberg, […]

The post Neil Jones is appointed as the new Chief Commercial Officer (CCO) of Aenova Group appeared first on International Pharmaceutical Industry.

Veröffentlicht am 04.08.2022 um 16:40:44 Uhr - Kategorie: News - Autor: theArchitect

Connect in Pharma

Connect in Pharma is the future of packaging, drug delivery & contract manufacturing for the pharma & biotech industry. Dedicated to the value chain downstream from the molecule and biotechnology, Connect in Pharma will drive innovation, business and new partnerships. Connect in Pharma 2022 – visitor registration form  

The post Connect in Pharma appeared first on International Pharmaceutical Industry.

Veröffentlicht am 02.08.2022 um 17:11:28 Uhr - Kategorie: Industry events - Autor: theArchitect

Cyclerion reveals data for schizophrenia therapy

Study data demonstrate the positive effects of CY6463 on cognition and inflammation. Cyclerion Therapeutics has announced positive top-line data from its clinical study of CY6463 for the treatment of Cognitive Impairment Associated with Schizophrenia (CIAS). It concerns individuals with stable schizophrenia on a stable, single, atypical antipsychotic regimen. CY6463 is a positive allosteric modulator of […]

The post Cyclerion reveals data for schizophrenia therapy appeared first on International Pharmaceutical Industry.

Veröffentlicht am 02.08.2022 um 11:50:06 Uhr - Kategorie: News - Autor: theArchitect

Tallac announces first patient treated with TAC-001

The phase 1/2 study is for patients with advanced or metastatic solid tumours. Tallac Therapeutics has announced that the first patient has been treated with TAC-001 in a phase 1/2 clinical trial for patients with advanced or metastatic solid tumours. TAC-001 is the company’s lead clinical candidate from its novel toll-like receptor agonist antibody conjugate […]

The post Tallac announces first patient treated with TAC-001 appeared first on International Pharmaceutical Industry.

Veröffentlicht am 02.08.2022 um 11:23:42 Uhr - Kategorie: News - Autor: theArchitect



Webhosting bei Alfahosting - jetzt kostenlos testen!